Top Markets
Coin of the day
Ever Supreme Bio Technology Co., Ltd Ever Supreme Bio Technology Co., Ltd

Ever Supreme Bio Technology Co., Ltd

6712
Rang in Aktien #13241
This enterprise is dedicated to the investigation, advancement, and creation of... This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Aktienkurs
$4.99
Marktkapitalisierung
$508.03M
Veränderung (1 Tag)
-2.48%
Veränderung (1 Jahr)
2.10%
Land
TW
Handel Ever Supreme Bio Technology Co., Ltd (6712)

Kategorie

Dividendenrendite-Verlauf für Ever Supreme Bio Technology Co., Ltd (6712)
Dividendenrendite (TTM) von Ever Supreme Bio Technology Co., Ltd (Aktienkürzel: 6712) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Ever Supreme Bio Technology Co., Ltd (6712) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH